BioAtla, Inc. BCAB 深 滬
已收盤 09-19 16:00:00 美东时间
1.74
+0.080
+4.82%
華盛通- 最 高1.785
- 今 開1.73
- 成交量 40.20万股
- 最 低 1.6898
- 昨 收 1.66
- 總市值 8340.83万
- 52周最高 4.02
- 市盈率 靜 --
- 換手率 0.84%
- 52周最低 1.14
- 委 比 65.55%
- 總股本 4793.58万
- 歷史最高 76.63
- 量 比 0.73
- 振 幅 5.73%
- 歷史最低 1.14
- 每 手 1
- 風險率 0.58%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多次贷“大空头”二季度大动作！股票投资组合砍半之际，增持阿里巴巴至头号持股
次贷危机时赚钱的“大空头”Michael Burry在今年二季度有大动作，当季进一步增持了阿里巴巴和百度股票，截至6月30日，阿里巴巴超越京东成为其最大持股。在...
08-15 05:25
BioAtla Q2 2024 GAAP EPS $(0.44), Inline
BioAtla (NASDAQ:BCAB) reported quarterly losses of $(0.44) per share which met the analyst consensus estimate.
08-09 04:27
BioAtla (BCAB) Receives a Buy from J.P. Morgan
J.P. Morgan analyst Brian Cheng reiterated a Buy rating on BioAtla (BCAB – Rese...
07-29 12:55
Buy Rating for BioAtla: Promising Clinical Assets and Undervaluation Present Investment Opportunity
In a report released today, Reni Benjamin from JMP Securities maintained a Buy ...
07-26 12:46
BioAtla Provides Clinical Program And Pipeline Updates At R&D Day
BioAtla Provides Clinical Program And Pipeline Updates At R&D Day
07-26 05:42
FDA grants fast track status to BioAlta's ozuriftamab vedotin
BioAlta (NASDAQ:BCAB) said the FDA has granted Fast Track Designation to its antibody drug conjugate ozuriftamab vedotin in the treatment of certain patients with squamous cell carcinoma of the head a...
07-23 23:29
Wall Street Analysts Are Bullish on Top Healthcare Picks
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts jus...
06-03 17:40
BioAtla to Participate in the Jefferies Global Healthcare Conference
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a glo...
05-29 20:00
LIDR, HOOK and BCAB among mid-day movers
Gainers: Innovative Eyewear (LUCY) +327%. OneMedNet Corp. (ONMD) +65%. Akanda Corp (AKAN) +57%. Merus N.V (MRUS) +35%. Netcapital (NCPL) +35%. Innovative Solutions And Support (ISSC) +29%. AEye (LIDR)...
05-25 00:58
HC Wainwright & Co.：重申BioAtla(BCAB.US)评级，由买入调整至买入评级, 目标价7.00美元。
HC Wainwright & Co.：重申BioAtla(BCAB.US)评级，由买入调整至买入评级, 目标价7.00美元。
05-15 23:20
